Similar articles

• Immune-related adverse events of checkpoint inhibitors.

  Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Ramos-Casals M, et al. Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6. Nat Rev Dis Primers. 2020. PMID: 32382051 Free PMC article. Review.
• Cancer immunotherapy-related adverse events: causes and challenges.

  Blidner AG, Choi J, Cooksley T, Dougan M, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Rapoport BL, Anderson R. Blidner AG, et al. Support Care Cancer. 2020 Dec;28(12):6111-6117. doi: 10.1007/s00520-020-05705-5. Epub 2020 Aug 28. Support Care Cancer. 2020. PMID: 32857220 Review.
• Immune-Checkpoint Blockade Therapy in Lymphoma.

  Kuzume A, Chi S, Yamauchi N, Minami Y. Kuzume A, et al. Int J Mol Sci. 2020 Jul 30;21(15):5456. doi: 10.3390/ijms21155456. Int J Mol Sci. 2020. PMID: 32751706 Free PMC article. Review.
• Immune checkpoint inhibitors: what neuro-ophthalmologists need to know.

  Douglas VP, Douglas KAA, Cestari DM. Douglas VP, et al. Curr Opin Ophthalmol. 2019 Nov;30(6):426-433. doi: 10.1097/ICU.0000000000000608. Curr Opin Ophthalmol. 2019. PMID: 31449088 Review.
• A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.

  Arnaud-Coffin P, Maillet D, Gan HK, Stelmes JJ, You B, Dalle S, Péron J. Arnaud-Coffin P, et al. Int J Cancer. 2019 Aug 1;145(3):639-648. doi: 10.1002/ijc.32132. Epub 2019 Feb 4. Int J Cancer. 2019. PMID: 30653255